In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHS Scotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within a particular health board because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The ADTC, Grampian Area Drug and Therapeutics Committee, is responsible for advising NHS Grampian health board on all aspects of the use of medicines.

Medicines routinely available within NHS Grampian are usually included in the Grampian Joint Formulary. The formulary is a list of medicines for use in the health board that has been agreed by the ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. A formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

How does the health board decide which new medicines to make routinely available for patients?

The ADTC in a health board will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in a health board.

Why is a particular medicine not routinely available in NHS Grampian?

- This is usually because the medicine is not recommended for use in NHS Scotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences as to which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

What happens if a particular medicine is not routinely available in NHS Grampian?

- If a medicine is not routinely available and not included in the Grampian Joint Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. All health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Grampian's latest decisions on medicines.

If you need more information on medicines decisions in NHS Grampian, please email gram.formularyteam@nhs.scot.



This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245.

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
anastrozole 1 mg film-coated tablets	113	The primary prevention of breast cancer in post-menopausal people at moderate or high risk.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024
axicabtagene ciloleucel 0.4 – 2 x 10^8 cells dispersion for infusion (Yescarta®)	2695	For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Routinely available in line with national guidance, SMC 2695 https://scottishmedicines.org.uk/media/8728/axicabtagene-yescarta-resubmission-final-oct-2024-for-website.pdf	19/11/2024
birch bark extract 23.4mg gel (Filsuvez®)	2651	For treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients aged 6 months and older.	Not routinely available in NHS Grampian. If local need identified, treatment is available through the National Services Scotland Ultra-orphan medicines Risk Share Scheme	19/11/2024
cabozantinib 20mg, 40mg, 60mg film-coated tablets (Cabozantinib Ipsen)	2386	In combination with nivolumab for the first-line treatment of advanced renal cell carcinoma in adults.	Routinely available in line with national guidance, SMC 2386 https://scottishmedicines.org.uk/media/6332/cabozantinib-cabometyx-abbreviated-final-sept-2021-for-website.pdf	19/11/2024
enzalutamide 40mg film-coated tablets (Xtandi®)	2742	As monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2742 https://scottishmedicines.org.uk/media/8730/enzalutamide-xtandi-non-sub-final-oct-2024-for-website.pdf	19/11/2024
follitropin delta 12micrograms/0.36mL, 36micrograms/1.08mL, 72micrograms/2.16mL solution for injection in a pre-filled pen (Rekovelle®)	2670	Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. **Restriction:** for use in normal responders (patients with an anti-Müllerian hormone level of >5.4 pmol/L) or high responders (patients with an anti-Müllerian hormone level of ≥25 pmol/L).	Routinely available in line with national guidance, SMC 2670 https://scottishmedicines.org.uk/media/8467/follitropin-delta-rekovelle-abb-final-june-2024-for-website.pdf	19/11/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Kay-Cee-L® 375mg/5mL syrup (potassium chloride)		For the treatment of hypokalaemia and potassium deficiency of renal and extrarenal origin.	This medicine is now withdrawn from use/discontinued	19/11/2024
Komboglyze® 2.5mg/1g tablets (saxagliptin/metformin)		In adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products (see sections 4.4, 4.5 and 5.1 of SmPC for available data on different combinations) - in patients already being treated with the combination of saxagliptin and metformin as separate tablets	This medicine is now withdrawn from use/discontinued	19/11/2024
lebrikizumab 250mg solution for injection in pre-filled syringe or pen (Ebglyss®)	2707	For the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40kg who are candidates for systemic therapy. **SMC restriction**: patients who have had an inadequate response to an existing systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable and where a biologic would otherwise be offered.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024
lenvatinib 4mg, 10mg hard capsules (Kisplyx®)	2199	In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.	Routinely available in line with national guidance, SMC 2199 https://scottishmedicines.org.uk/media/4885/lenvatinib-kisplyx-final-oct-2019-for-website.pdf	19/11/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
lenvatinib 4mg, 10mg hard capsules (Kisplyx®)	2476	Treatment of adults with advanced renal cell carcinoma (RCC), in combination with pembrolizumab, as first-line treatment. **Restriction:** treatment with pembrolizumab is subject to a two-year clinical stopping rule.	Routinely available in line with national guidance, SMC 2476 https://scottishmedicines.org.uk/media/6933/lenvatinib-kisplyx-abb-final-may-2022-for-website.pdf	19/11/2024
linzagolix 100mg, 200mg film-coated tablets (Yselty®)	2631	The treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. **SMC restriction**: for use in patients when conventional first-line treatments (such as tranexamic acid, hormonal contraceptives and intrauterine devices) have failed or are considered unsuitable.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024
momelotinib 100mg, 150mg, 200mg film coated tablet (Omjjara®)	2636	Treatment of disease-related splenomegaly or symptoms in adults with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.	Routinely available in line with national guidance, SMC 2636 https://scottishmedicines.org.uk/media/8384/momelotonib-omjjara-abb-final-may-2024-for-website.pdf	19/11/2024
NovoRapid® FlexTouch 100units/mL (insulin aspart)		For treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.	This medicine is now withdrawn from use/discontinued	19/11/2024
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2688	In combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for the treatment of resectable non-small cell lung carcinoma at high risk of recurrence in adults.	Not routinely available as not recommended for use in NHS Scotland, SMC 2688 https://scottishmedicines.org.uk/media/8733/pembrolizumab-keytruda-final-oct-2024-for-website.pdf	19/11/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Pylera® 140mg/125mg/125mg hard capsules (bismuth subcitrate potassium/ metronidazole/ tetracycline hydrochloride)	2701	In combination with omeprazole, for the eradication of *Helicobacter pylori* and prevention of relapse of peptic ulcers in patients with active or a history of *H. pylori* associated ulcers. **SMC restriction**: restricted to use in accordance with clinical guidelines for the eradication of *H. pylori* .	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024
quizartinib 17.7mg, 26.5mg film-coated tablets (Vanflyta®)	2699	In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024
raloxifene 60mg film-coated tablets	114	[Off label use] for the primary prevention of breast cancer in post-menopausal people at moderate or high risk who are not suitable for on-label alternatives.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024
ribociclib 200mg film-coated tablets (Kisqali®)	2198	For the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. **Restriction:** women who have relapsed on or within 12 months of completing (neo) adjuvant endocrine therapy, or those who have progressed on first-line endocrine-based therapy for advanced breast cancer.	Routinely available in line with national guidance, SMC 2198 https://scottishmedicines.org.uk/media/4888/ribociclib-kisqali-final-october-2019-for-website.pdf	19/11/2024

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
somapacitan 10mg/1.5mL, 15mg/1.5mL solution for injection in pre-filled pen (Sogroya®)	2629	For the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD). **SMC restriction**: for children aged 3 years and above and adolescents with growth failure due to growth hormone deficiency (paediatric GHD).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024
sunitinib 12.5mg, 25mg hard capsules	111	As second line treatment of poor or intermediate risk advanced/metastatic renal cell carcinoma in patients who have received nivolumab in combination with ipilimumab as first line treatment.	Routinely available in line with national guidance, NCMAG 111 https://www.healthcareimprovementscotland.scot/wp-content/uploads/2024/02/NCMAG111-Sunitinib-Advice-Document-v1.00e06.pdf	19/11/2024
tamoxifen 20mg tablets	115	For the primary prevention of breast cancer in people at moderate or high risk.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024
tenecteplase 5,000 units (25mg) powder for solution for injection (Metalyse®)	2697	In adults for the thrombolytic treatment of acute ischaemic stroke within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024
trametinib dimethyl sulfoxide 2mg film-coated tablets (Mekinist®)	118	[Off-label use] for the treatment of low grade serous ovarian cancer after at least one line of platinum-based chemotherapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2024
Victoza® 6mg/mL solution for injection in pre-filled pen (liraglutide)		For the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: - as monotherapy when metformin is considered inappropriate due to intolerance or contraindications - in addition to other medicinal products for the treatment of diabetes	This medicine is now withdrawn from use/discontinued	19/11/2024